News und Analysen
![Transgene Presents Promising New Data from its Next-Generation Immunotherapy Platforms at AACR 2020](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Transgene Presents Promising New Data from its Next-Generation Immunotherapy Platforms at AACR 2020
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, presents its broad viral vector expertise and their
![Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines
Pfizer Inc. (NYSE:PFE) today announced the initiation of four Phase 3 clinical trials within its current pipeline of investigational vaccines:
-
Two studies (NCT04382326 and NCT04379713) of the
![Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines
Pfizer Inc. (NYSE:PFE) today announced the initiation of four Phase 3 clinical trials within its current pipeline of investigational vaccines:
-
Two studies (NCT04382326 and NCT04379713) of the
![Lantheus Completes Merger with Progenics](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Lantheus Completes Merger with Progenics
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of
![Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications
![Premier Inc. Creates Oncology-Focused Purchasing Alliance with 20 Leading Cancer Providers to Source Branded Cancer Drugs](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Premier Inc. Creates Oncology-Focused Purchasing Alliance with 20 Leading Cancer Providers to Source Branded Cancer Drugs
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today debuted Intersectta®, a new oncology-focused group purchasing organization (GPO) to source cancer and other specialty
![Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy
Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec
![Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy
Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec
![Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene
![Humana’s 2020 Bold Goal Progress Report Details Improved Mental and Physical Health Among its Population](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Humana’s 2020 Bold Goal Progress Report Details Improved Mental and Physical Health Among its Population
Humana Inc. (NYSE: HUM) today unveiled its “2020 Bold Goal Progress Report,” which details the company’s progress in its ambitious population health strategy launched in 2015 to improve the health
![Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn
Upjohn Inc. (“Newco”), a wholly-owned subsidiary of Pfizer Inc. (“Pfizer”) (NYSE: PFE), Upjohn Finance B.V. (“Finco”), a wholly-owned subsidiary of Newco, Pfizer and Mylan N.V. (“Mylan”) (Nasdaq
![Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn
Upjohn Inc. (“Newco”), a wholly-owned subsidiary of Pfizer Inc. (“Pfizer”) (NYSE: PFE), Upjohn Finance B.V. (“Finco”), a wholly-owned subsidiary of Newco, Pfizer and Mylan N.V. (“Mylan”) (Nasdaq
![Illumina Acquires BlueBee to Accelerate Processing, Analysis and Sharing of Next Generation Sequencing Data at Scale](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Illumina Acquires BlueBee to Accelerate Processing, Analysis and Sharing of Next Generation Sequencing Data at Scale
Illumina, Inc. (NASDAQ: ILMN) is enhancing its capabilities to analyze and interpret the data produced by its sequencing systems with the acquisition of BlueBee, a cloud-based software company that
![Illumina Acquires BlueBee to Accelerate Processing, Analysis and Sharing of Next Generation Sequencing Data at Scale](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Illumina Acquires BlueBee to Accelerate Processing, Analysis and Sharing of Next Generation Sequencing Data at Scale
Illumina, Inc. (NASDAQ: ILMN) is enhancing its capabilities to analyze and interpret the data produced by its sequencing systems with the acquisition of BlueBee, a cloud-based software company that
![Illumina Acquires BlueBee to Accelerate Processing, Analysis and Sharing of Next Generation Sequencing Data at Scale](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Illumina Acquires BlueBee to Accelerate Processing, Analysis and Sharing of Next Generation Sequencing Data at Scale
Illumina, Inc. (NASDAQ: ILMN) is enhancing its capabilities to analyze and interpret the data produced by its sequencing systems with the acquisition of BlueBee, a cloud-based software company that
![Waters Corporation Announces CEO Succession Plan](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Waters Corporation Announces CEO Succession Plan
Waters Corporation (NYSE:WAT) today announced that the Company’s Board of Directors and Christopher O’Connell have mutually agreed that Mr. O’Connell will step down as President, Chief Executive
![Nanobiotix Receives Feedback From US FDA to Advance Phase III Head and Neck Cancer Study Design and CMC Development Plan for NDA](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Nanobiotix Receives Feedback From US FDA to Advance Phase III Head and Neck Cancer Study Design and CMC Development Plan for NDA
Regulatory News:
“With our recent Fast Track designation for NBTXR3 in this patient population, acceptance of the design of our pivotal phase III trial and agreement on our CMC plan, Nanobiotix
![Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that four abstracts showcasing non-clinical data from rucaparib and lucitanib development programs have been accepted for on-demand viewing and
![NanoString Announces New Products to Advance COVID-19 Disease Research](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
NanoString Announces New Products to Advance COVID-19 Disease Research
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the availability of new solutions to study the immune
![Illumina Inc. Announces that U.S. Federal Court Issues Preliminary Injunction Against BGI Companies](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Illumina Inc. Announces that U.S. Federal Court Issues Preliminary Injunction Against BGI Companies
Illumina, Inc. (NASDAQ: ILMN) today announced that the U.S. District Court for the Northern District of California issued a preliminary injunction order against several BGI companies, including MGI
![Illumina Inc. Announces that U.S. Federal Court Issues Preliminary Injunction Against BGI Companies](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Illumina Inc. Announces that U.S. Federal Court Issues Preliminary Injunction Against BGI Companies
Illumina, Inc. (NASDAQ: ILMN) today announced that the U.S. District Court for the Northern District of California issued a preliminary injunction order against several BGI companies, including MGI
![Illumina Inc. Announces that U.S. Federal Court Issues Preliminary Injunction Against BGI Companies](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Illumina Inc. Announces that U.S. Federal Court Issues Preliminary Injunction Against BGI Companies
Illumina, Inc. (NASDAQ: ILMN) today announced that the U.S. District Court for the Northern District of California issued a preliminary injunction order against several BGI companies, including MGI
![Lantheus Stockholders Approve Share Issuance For Merger with Progenics](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Lantheus Stockholders Approve Share Issuance For Merger with Progenics
Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of
![Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 28, 2020. The purpose
![Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 28, 2020. The purpose